Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Apr 17, 2021 1:06am
163 Views
Post# 33016370

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:AGM our on Sedar

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:AGM our on Sedar

I agree.  We need a solid Q1 ideally filed by May 14 not last minute on May 17.  Ideally over $4 million   Since Q1 is Jan-March we won't see any Aristotle revenue so we need updates over the next 4 weeks on the roll out, other partners and a big marketing blitz.  Marketing is not a couple posts on social media. I'm talking a significant spend and national exposure.  

if those 2 things don't happen I can see a real chance Tripp is in trouble at the meeting   


Mermer2328 wrote:
A monster Q1, will not make a difference. Aristotle,Aristotle,Aristotle. Tripp starts every interview talking about 20yrs of work to develop the best Cancer detection test on earth. That's why we all invested.. The half hearted attempt at a roll out will be his demise.. I cant currently see anything that would make me change my mind, unless we get a huge Aristotle adoption NR

 

<< Previous
Bullboard Posts
Next >>